127 related articles for article (PubMed ID: 35480123)
1. Case Report: Olaparib Shows Satisfactory Clinical Outcomes Against Small Cell Esophageal Carcinoma With
Wang W; Zhang X; Fang Y; He J; Huang J; Li S; Ma T; Li L
Front Oncol; 2022; 12():808801. PubMed ID: 35480123
[TBL] [Abstract][Full Text] [Related]
2. Integrated Genome-Wide Analysis of Gene Expression and DNA Copy Number Variations Highlights Stem Cell-Related Pathways in Small Cell Esophageal Carcinoma.
Liu D; Xu X; Wen J; Xie L; Zhang J; Shen Y; Jiang G; Chen J; Fan M
Stem Cells Int; 2018; 2018():3481783. PubMed ID: 30228821
[No Abstract] [Full Text] [Related]
3. Olaparib: A Review as First-Line Maintenance Therapy in Advanced Ovarian Cancer.
Paik J
Target Oncol; 2021 Nov; 16(6):847-856. PubMed ID: 34623572
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Combination of Olaparib With Chemotherapy in a Patient With ATM-Deficient Colorectal Cancer.
Papageorgiou GI; Fergadis E; Skouteris N; Christakos E; Tsakatikas SA; Lianos E; Kosmas C
Front Oncol; 2021; 11():788809. PubMed ID: 35004311
[TBL] [Abstract][Full Text] [Related]
5. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations.
Marshall CH; Sokolova AO; McNatty AL; Cheng HH; Eisenberger MA; Bryce AH; Schweizer MT; Antonarakis ES
Eur Urol; 2019 Oct; 76(4):452-458. PubMed ID: 30797618
[TBL] [Abstract][Full Text] [Related]
6. A Comparative Analysis of the Gene Expression Profiles of Small Cell Esophageal Carcinoma, Small Cell Lung Cancer, and Esophageal Adeno/Squamous Carcinoma.
Liu D; Wen J; Chen J; Wang B; Xu X; Zhang Z; Fan M
Front Surg; 2021; 8():655159. PubMed ID: 34395507
[No Abstract] [Full Text] [Related]
7. Effectiveness of Olaparib Treatment in a Patient with Gallbladder Cancer with an ATM-Inactivating Mutation.
Zhang W; Shi J; Li R; Han Z; Li L; Li G; Yang B; Yin Q; Wang Y; Ke Y; Li Q
Oncologist; 2020 May; 25(5):375-379. PubMed ID: 32045060
[TBL] [Abstract][Full Text] [Related]
8. Remarkable Response to the Triplet Combination of Olaparib with Pembrolizumab and Bevacizumab in the Third-Line Treatment of an Ovarian Clear Cell Carcinoma Patient with an ARID1A Mutation: A Case Report.
Zhao Y; Jiang Y
Onco Targets Ther; 2022; 15():323-328. PubMed ID: 35401005
[TBL] [Abstract][Full Text] [Related]
9. Homologous recombination deficiency and ovarian cancer.
Ledermann JA; Drew Y; Kristeleit RS
Eur J Cancer; 2016 Jun; 60():49-58. PubMed ID: 27065456
[TBL] [Abstract][Full Text] [Related]
10. PARP inhibitor resistance and TP53 mutations in patients treated with olaparib for BRCA-mutated cancer: Four case reports.
Collot T; Niogret J; Carnet M; Chevrier S; Humblin E; Favier L; Bengrine-Lefevre L; Desmoulins I; Arnould L; Boidot R
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236159
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of different treatments of limited-stage small-cell esophageal carcinoma and associated prognostic factor analysis.
Ding J; Ji J; Zhu W; Zhou K; Han J; Zhang Y; Yu C; Li T; Tao G; Ji F; Zhou X; Pan P
Dis Esophagus; 2013; 26(7):696-702. PubMed ID: 23317069
[TBL] [Abstract][Full Text] [Related]
12. Case Report: BAP1 Mutation and RAD21 Amplification as Predictive Biomarkers to PARP Inhibitor in Metastatic Intrahepatic Cholangiocarcinoma.
Sabbatino F; Liguori L; Malapelle U; Schiavi F; Tortora V; Conti V; Filippelli A; Tortora G; Ferrone CR; Pepe S
Front Oncol; 2020; 10():567289. PubMed ID: 33330039
[TBL] [Abstract][Full Text] [Related]
13. Olaparib for the treatment of metastatic prostate cancer.
Dror CM; Wyatt AW; Chi KN
Future Oncol; 2021 Jul; 17(19):2413-2429. PubMed ID: 33769071
[TBL] [Abstract][Full Text] [Related]
14. Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.
Kubota E; Williamson CT; Ye R; Elegbede A; Peterson L; Lees-Miller SP; Bebb DG
Cell Cycle; 2014; 13(13):2129-37. PubMed ID: 24841718
[TBL] [Abstract][Full Text] [Related]
15. Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.
Hodgson D; Lai Z; Dearden S; Barrett JC; Harrington EA; Timms K; Lanchbury J; Wu W; Allen A; Senkus E; Domchek SM; Robson M
Ann Oncol; 2021 Dec; 32(12):1582-1589. PubMed ID: 34500047
[TBL] [Abstract][Full Text] [Related]
16. TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.
Tung NM; Robson ME; Ventz S; Santa-Maria CA; Nanda R; Marcom PK; Shah PD; Ballinger TJ; Yang ES; Vinayak S; Melisko M; Brufsky A; DeMeo M; Jenkins C; Domchek S; D'Andrea A; Lin NU; Hughes ME; Carey LA; Wagle N; Wulf GM; Krop IE; Wolff AC; Winer EP; Garber JE
J Clin Oncol; 2020 Dec; 38(36):4274-4282. PubMed ID: 33119476
[TBL] [Abstract][Full Text] [Related]
17. ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.
Wang C; Jette N; Moussienko D; Bebb DG; Lees-Miller SP
Transl Oncol; 2017 Apr; 10(2):190-196. PubMed ID: 28182994
[TBL] [Abstract][Full Text] [Related]
18. Transient Response of Olaparib on Pulmonary Artery Sarcoma Harboring Multiple Homologous Recombinant Repair Gene Alterations.
Wu CE; Ng CT; Tan KT
J Pers Med; 2021 Apr; 11(5):. PubMed ID: 33946955
[TBL] [Abstract][Full Text] [Related]
19. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
Kaye SB
Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i1-i3. PubMed ID: 27141062
[TBL] [Abstract][Full Text] [Related]
20. Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations).
Mahdi H; Hafez N; Doroshow D; Sohal D; Keedy V; Do KT; LoRusso P; Jürgensmeier J; Avedissian M; Sklar J; Glover C; Felicetti B; Dean E; Mortimer P; Shapiro GI; Eder JP
JCO Precis Oncol; 2021; 5():. PubMed ID: 34527850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
